Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.80 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.80 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.80 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.80 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302850 | 1.00 | ABCB11 (0.80) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL14356353 | 1.00 | ABCB11 (0.80) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL30063061 | 1.00 | ABCB11 (0.80) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL14252218 | 0.94 | ABCB11 (0.79) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23541658 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23541652 | 0.93 | MAPT (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23594215 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29559659 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23510705 | 0.93 | MAPT (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL31447566 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102392-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | MEDILABO RFP INC (JP) | 2026-04-16 | — | — | US | claimed |
| US-12521387-B2 | Prophylactic or therapeutic drug for neurodegenerative diseases | MEDILABO RFP, INC. (JP) | 2026-01-13 | — | — | US | claimed |
| US-20250120943-A1 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | AMD THERAPEUTICS LLC (US) | 2025-04-17 | — | — | US | claimed |
| EP-4531844-A1 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | AMD Therapeutics LLC (US) | 2025-04-09 | — | — | EP | claimed |
| CN-119300821-A | Ophthalmic compositions of rifamycin and uses thereof | AMD治疗有限责任公司 | 2025-01-10 | — | — | CN | claimed |
| WO-2023234423-A1 | RIFAMYCIN OPHTHALMIC COMPOSITION AND USE THEREOF | AMD THERAPEUTICS LLC (US) | 2023-12-07 | — | — | WO | claimed |
| EP-3650024-B1 | PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION COMPRISING RIFAMPICINS FOR TREATING DEMENTIA | MEDILABO RFP INC (JP) | 2023-10-25 | — | — | EP | claimed |
| CN-113933399-B | Method for separating and detecting rifampicin and related impurities in rifampicin for injection | 重庆华邦制药有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-115656364-A | Detection method of related substances in rifampicin and application of detection method in MNP (MNP) monitoring | 中国食品药品检定研究院 | 2023-01-31 | — | — | CN | claimed |
| CN-122080018-A | Synthetic process for preparing rifampicin by using rifamycin O as starting material | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4736953-A2 | THERAPEUTIC AGENTS AND METHODS | Pop Test Oncology LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260102392-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | MEDILABO RFP INC (JP) | 2026-04-16 | — | — | US | disclosed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4706655-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASE | Medilabo RFP, Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-11583494-B2 | Pharmaceutical composition for nasal administration | MEDILABO RFP, INC. (JP) | 2023-02-21 | — | — | US | disclosed |
| CN-115656364-A | Detection method of related substances in rifampicin and application of detection method in MNP (MNP) monitoring | 中国食品药品检定研究院 | 2023-01-31 | — | — | CN | disclosed |
| WO-2023284777-A1 | COPOLYMER FILM, ENZYME CATALYSIS SELF-ASSEMBLY SYNTHESIS METHOD THEREFOR, AND APPLICATION THEREOF | 中国科学院天津工业生物技术研究所 | 2023-01-19 | — | — | WO | disclosed |
| US-20220298203-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC | 2022-09-22 | — | — | US | disclosed |
| US-11447502-B2 | Antibacterial agents: dual-targeted RNA polymerase inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220125782-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | MEDILABO RFP, INC. (JP) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583494-B2 | Pharmaceutical composition for nasal administration | NPC1, CYP3A43, ABCB11 | ABCB11 3/4885MAPT 28/4885ABCC4 122/4885 |
| US-11447502-B2 | Antibacterial agents: dual-targeted RNA polymerase inhibitors | POLM, POLR2E, POLR2H | ABCB11 1452/4885MAPT 3318/4885ABCC4 3222/4885 |
| US-20220125782-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | HTT, SIRT1, NRDC | ABCB11 385/4885MAPT 6/4885ABCC4 553/4885 |
| US-20220298203-A1 | THERAPEUTIC AGENTS AND METHODS | NR1H4, NR3C1, NR3C2 | ABCB11 715/4885MAPT 4807/4885ABCC4 3201/4885 |
| US-20260102392-A1 | PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES | MAPT, SNCA, FUS | ABCB11 488/4885MAPT 1/4885ABCC4 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.